Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Shares Outstanding: 2022-2025

Historic Shares Outstanding for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to $56.5 million.

  • Orchestra BioMed Holdings' Shares Outstanding rose 48.81% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 48.81%. This contributed to the annual value of $38.2 million for FY2024, which is 6.76% up from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Shares Outstanding is $56.5 million, which was up 46.12% from $38.6 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' Shares Outstanding's 5-year high stood at $56.5 million during Q3 2025, with a 5-year trough of $10.1 million in Q1 2022.
  • Its 3-year average for Shares Outstanding is $38.2 million, with a median of $35.8 million in 2024.
  • Data for Orchestra BioMed Holdings' Shares Outstanding shows a peak YoY surged of 213.13% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Orchestra BioMed Holdings' Shares Outstanding stood at $35.7 million in 2022, then rose by 0.23% to $35.8 million in 2023, then climbed by 6.76% to $38.2 million in 2024, then skyrocketed by 48.81% to $56.5 million in 2025.
  • Its Shares Outstanding was $56.5 million in Q3 2025, compared to $38.6 million in Q2 2025 and $38.3 million in Q1 2025.